SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending as President Trump's threats of new tariffs on European nations over Greenland escalate geopolitical tensions, leading to a risk-off market sentiment. The community is divided, with some anticipating a significant market pullback, while others view it as a 'buy the dip' opportunity, also noting a Japan-led bond sell-off as a contributing factor. This environment is fueling discussions about broader market volatility and a flight to safe-haven assets.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following Saudi Arabia's approval of its Anktiva-based Bioshield protocol for non-small cell lung cancer and broader cancer treatment, alongside ongoing discussions with the FDA for papillary bladder cancer. The community is passionately discussing the potential for a significant short squeeze, viewing the company as a disruptive force in oncology while expressing strong frustration with perceived FDA delays.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is actively trending amid escalating US-EU trade tensions driven by President Trump's tariff threats over Greenland, sparking a widespread market sell-off and global risk-off sentiment. The investment community is sharply divided between those anticipating a deeper correction for technology and growth stocks and fervent "buy the dip" proponents. Immediate market focus remains on an upcoming Supreme Court ruling regarding tariff authority and a heavy week of earnings reports, amplifying uncertainty.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group Corp. (DJT) is trending amidst intense debate spurred by former President Trump's controversial push for tariffs against European nations, reportedly tied to his interest in Greenland and past grievances. This situation has ignited polarized community discussions concerning potential trade wars and geopolitical repercussions, with many weighing economic stability against his "America First" agenda.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Holdings Inc

Ondas Holdings is generating significant buzz following a substantial upward revision to its future revenue outlook and a surging order backlog, further bolstered by a recent large capital raise. The community is actively discussing its promising potential as a rapidly expanding defense and autonomy platform, especially amidst ongoing negotiations for key acquisitions in the critical drone technology sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is a major talking point following its J.P. Morgan conference appearance, where investors are eagerly seeking clarity on its strategy for advancing the Matrix-M adjuvant technology and securing new collaborations. Community sentiment is sharply focused on management's pace in realizing pipeline potential, including a recent Pfizer agreement and ongoing Sanofi ventures, with an activist investor's growing stake and significant short interest adding to the intense market watch.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas ($BOIL) is trending due to a significant surge in natural gas futures, driven by widespread forecasts for severe arctic cold fronts across the US, intensifying heating demand expectations. The community is actively debating the potential for a powerful short squeeze amidst historically high short interest, while also acknowledging the inherent volatility and decay of leveraged natural gas ETFs like $BOIL, often referred to as a "widow maker". Discussions highlight the impact of this weather event on depleting storage levels, yet some remain cautious, pointing to broader warm winter trends and structural factors like contango, questioning the rally's sustainability.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin (APP) is trending following an investigative report alleging the company's involvement in money laundering for a Southeast Asian gambling group, which has sparked a sharp market sell-off. While some in the community are expressing serious concerns and anticipating further declines, many long-term investors are dismissing the report as a rehashed short attack and are actively buying the dip, expecting a strong rebound following upcoming earnings and management's anticipated defense of the allegations.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending as investors react to a significant patent extension for its key products until 2041, coupled with a bullish preliminary business update accelerating IBSRELA's path to $1 billion in revenue by 2029 and multiple analyst price target upgrades. The community is buzzing with renewed acquisition speculation and optimism over the company's long-term value, despite ongoing discussions about short-term price fluctuations attributed to market dynamics. This confluence of positive developments has many viewing Ardelyx as a significantly undervalued biotech with strong commercial execution.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is trending after announcing positive data from its placebo-controlled Phase 1 clinical trial of soquelitinib for atopic dermatitis, showing strong efficacy. The community is actively discussing the oral ITK inhibitor's potential in a large market, with many anticipating significant revaluation and partnership opportunities for its novel mechanism of action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>A Supreme Court ruling on tariffs and the U.S. jobs report were scheduled for Friday.</li><li>Housing, biotech and aviation stocks saw notable moves during regular and extended trading.</li><li>Markets tracked developments related to trade policy, mortgage bonds and economic data.</li></ul>U.S. stock futures were mixed late Thursday as investors positioned cautiously ahead of a key U.S. jobs report and weighed a series of policy signals out of Washington that could influence trade, rates, and housing markets.As of 9.05 P.M. ET, Nasdaq 100 futures were down 0.2%, while S&amp;P 500 futures&nbsp;were down by 0.1%. Dow futures were up 0.6%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> was ‘neutral’, while sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> was ‘bullish’ and sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘extremely bearish’, all amid ‘high’ message volume.<h2 class="st-heading-2">Market Drivers</h2>Markets reacted to two potential catalysts heading into Friday: a possible ruling from the U.S. Supreme Court on the legality of tariffs imposed under President Donald Trump and his latest comments on mortgage markets.In the prior session, the Dow Jones Industrial Average rose 0.6%, while the S&amp;P 500 climbed 0.01% and the Nasdaq Composite slid 0.4%.Trump said in a social media post on Thursday that he is instructing his representatives to&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-instructs-to-buy-200-billion-dollars-in-mortgage-bonds/cmUbZfwR45k">buy $200 billion in mortgage bonds</a>, arguing that the move would help lower mortgage rates and monthly payments. He added that Fannie Mae and Freddie Mac have about $200 billion in cash, framing the directive as a way to make homeownership more affordable.The comments came a day after Trump said he would&nbsp;seek to ban large institutional investors from buying single-family homes, citing rising inflation and high housing costs as a growing barrier for younger Americans.<h2 class="st-heading-2">Peter Schiff Pushes Back On Mortgage Bond Buying</h2>Economist Peter Schiff&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/PeterSchiff/status/2009416426738626693">said on X</a> that lower home prices, rather than additional credit, were the only solution to the housing affordability crisis. He argued that directing more government-backed credit into the mortgage market would allow buyers to stretch further and overpay for homes, worsening the problem.Schiff also said&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/PeterSchiff/status/2009391071760142624">in a separate post</a> that if the $200 billion were sourced from government-sponsored entities, it could reduce availability for U.S. Treasuries. While such purchases might temporarily push mortgage rates lower, he warned they could also lead to higher Treasury yields and increased inflation pressures.<h2 class="st-heading-2">Trending Stocks To Watch</h2>Opendoor Technologies: Shares jumped more than 12% after hours after rising about 5% in regular trading, as comments on mortgage-related policy lifted housing-linked stocks.Rocket Companies: The stock gained 7% in extended trading after slipping 0.2% during the regular session, also moving on mortgage and rate-related news.Aclarion: Shares fell about 13% after hours after surging more than 42% in regular trading, following an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/acon-stock-pops-pre-market-today-what-s-driving-the-move/cmUbeT3R4Pp">update on business progress</a>, rising demand for its Nociscan platform, and its financial position heading into 2026.flyExclusive: The stock more than doubled during regular trading, up over 130%, after the company announced an&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/flyx-stock-surges-130-percent-whats-the-spacex-connection/cmUbfvrR45T">authorized dealership agreement with Starlink</a> to install high-speed connectivity across its fleet.Oscar Health: Shares rose nearly 7% after hours after gaining about 3% in regular trading, as&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/oscar-health-stock-surges-over-after-hours-as-house-backs-obamacare-subsidies/cmUcxWmR45N">investors reacted to a House vote backing</a> ACA subsidy extensions, despite a disclosed insider share sale.Enliven Therapeutics: The stock added about 1% after hours after soaring roughly 50% during the session, following positive early data from its&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-elvn-stock-shoot-up-60-percent-today/cmUbQNvR45E">Phase 1b Enable trial</a> for ELVN-001 in chronic myeloid leukemia.<h2 class="st-heading-2">Broader Markets</h2>In broader markets, oil prices rebounded after two straight days of declines, settling at a two-week high. Brent crude rose $2.03, or 3.4%, to $61.99 a barrel, while U.S. West Texas Intermediate gained $1.77, or 3.2%, to $57.76.&nbsp;The yield on the benchmark 10-year U.S. Treasury was last around 4.18%. Asian equities were mixed, with shares opening higher in Japan and Australia, while South Korea lagged.Among the catalysts for the day are housing starts and building permits figures, updated University of Michigan consumer sentiment readings, and remarks from Minneapolis Fed President Neel Kashkari and Richmond Fed President Tom Barkin.For updates and corrections, email newsroom[at]stocktwits[dot]com.

People walk past the New York Stock Exchange (NYSE) on August 22, 2025, in New York City. (Photo by Spencer Platt/Getty Images)

S&P 500, Nasdaq Futures Waver Ahead Of Supreme Court Ruling On Trump Tariffs: Why OPEN, ACON, FLYX, OSCR Are Trending After-Hours

Attention also centered on Trump’s comments on proposed mortgage bond purchases.

Equity

Healthcare Stocks To Keep An Eye On - January 8th

UnitedHealth Group, Johnson & Johnson, Intuitive Surgical, Aclarion, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. As it...

<ul class="summary-bullets"><li>In 2025, Aclarion added nine imaging sites and more than 20 new physician users.</li><li>The company reported a 69% increase in annual scan volume, capped by triple-digit growth in the fourth quarter.</li><li>Looking to 2026, the company expects to speed up CLARITY trial enrollment, and roll out a new version of its software to improve workflow integration.&nbsp;</li></ul>Aclarion, Inc. (ACON) stock shot up over 45% on Thursday’s premarket after the company shared an overview of its latest business progress and financial performance as it heads into 2026 and continues to develop its Nociscan platform.The healthcare technology company focuses on helping physicians pinpoint the source of chronic lower back pain using biomarkers and advanced analytics embedded in its Nociscan platform.<h2 class="st-heading-2">Momentum Gained In 2025</h2>Demand for Nociscan continued to accelerate through 2025, with scan volumes rising sharply across the U.S., the U.K., and Europe as new imaging centers and physician users came onboard.In 2025, Aclarion added nine imaging sites and more than 20 new physician users. The company said these steps supported a 69% increase in annual scan volume, capped by triple-digit growth in the fourth quarter.On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/ACON">Aclarion stock</a> jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume shifted to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_08_073305_png_e7268d46e3.webp" alt="ACON’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Jan. 8, 2026 | Source: Stocktwits" width="932" height="104"><figcaption>ACON’s Sentiment Meter and Message Volume as of 07:30 a.m. ET on Jan. 8, 2026 | Source: Stocktwits</figcaption></figure>Aclarion launched its CLARITY trial in 2025, activating seven sites to evaluate real-world performance. The company also published data indicating Nociscan could lower per-patient costs and improve surgical success rates.<h2 class="st-heading-2">Plans For 2026</h2>Looking to 2026, the company expects to speed up CLARITY trial enrollment, expand compatibility with additional MRI manufacturers, and roll out a new version of its software to improve workflow integration.&nbsp;<blockquote>“We are pleased with the progress Aclarion has made in strengthening our financial position, expanding clinical traction, and advancing Nociscan toward broader adoption.”- Brent Ness, CEO, Aclarion</blockquote>As of the end of 2025, Aclarion reported $12 million in cash and no outstanding debt. Based on current spending levels, the company said it has sufficient resources to operate into the first half of 2027.ACON stock has declined by over 99% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/exclusive-richtech-robotics-coo-bets-on-single-use-robots-as-dex-targets-real-world-labor-gaps/cmUb5USR4Pj">Exclusive: Richtech Robotics COO Bets On Single-Use Robots As Dex Targets Real-World Labor Gaps</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Aclarion logo is seen displayed on a smartphone screen.

ACON Stock Pops 45% Pre-Market Today: What’s Driving The Move?

The company said demand for Nociscan continued to accelerate through 2025, with scan volumes rising sharply across the U.S., the U.K., and Europe as new imaging centers and physician users came onboard.

AMN Healthcare Services (AMN) Tops Q2 Earnings and Revenue Estimates

AMN Healthcare (AMN) delivered earnings and revenue surprises of +76.47% and +0.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Healthcare technology firm Aclarion Inc.'s (ACON) stock surged nearly 127% on Monday, marking its best single-day gain since going public in 2022.&nbsp;The surge followed news that Aclarion has entered into a commercial agreement with Scripps Health, bringing its Nociscan technology — a noninvasive tool that helps physicians personalize treatment for chronic lower back pain — to Scripps' network of doctors in San Diego, California.Aclarion says the deal will allow Scripps physicians to better differentiate between painful and non-painful lumbar discs using magnetic resonance spectroscopy and advanced signal processing.&nbsp;While the partnership's financial terms were not disclosed, the news generated widespread enthusiasm among retail traders, driving a dramatic surge in trading activity and online discussions.Investor chatter on Stocktwits turned sharply bullish in response to the announcement. The company's follower count on the platform jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.A Stocktwits poll found that 41% of more than 1,100 retail traders view the partnership as a "game-changer," while 32% describe it as "short-term hype, long-term unknown." The remaining see it as a "liquidity event" or too early to make a definitive judgment.Retail traders debated the deal's broader implications, with one suggesting that it could make Aclarion a potential acquisition target for major medical technology firms.&nbsp;One user speculated that a buyout by a company like Medtronic could send the stock significantly higher, while another dismissed concerns about potential dilution, predicting a run to $10–$20.<stembedurl>https://stocktwits.com/TraderMitsos/message/606583790</stembedurl><stembedurl>https://stocktwits.com/Hotoilguy/message/606598370</stembedurl>Aclarion, which has a market capitalization of just $7.7 million, remains an early-stage company that has yet to generate revenue.&nbsp;Short interest on the stock has jumped from 11.8% at the start of 2025 to 24.2% by the end of last week, according to Koyfin.Following Monday's rally, <a href="https://stocktwits.com/symbol/ACON">Aclarion shares</a> are now up over 5% year-to-date. According to Koyfin data, only two analysts currently cover Aclarion, with one rating it a 'Buy' and the other a 'Hold.'The stock was seeing heavy profit-taking in Monday's after-hours trading, falling over 14%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Is Aclarion's Tie-Up With Scripps Health A Lasting Catalyst? Most Retail Traders Think It's A 'Game-Changer'

The company's follower count on Stocktwits jumped nearly 20%, while message volume surged by over 6,000% by the end of Monday's session.

Aclarion Inc. shares surged 94% on Thursday afternoon in heavy trading after the healthcare technology company executed a 1-for-335 reverse stock split.&nbsp;The move reduced its outstanding common shares from approximately 169.4 million pre-split to around 500,000 post-split.The reverse split propelled Aclarion to the top of Stocktwits’ trending tickers, with its retail following jumping 59% from Wednesday’s close.&nbsp;Bullish traders speculated the stock could climb another 45% from current levels, while some anticipated a near-tripling.<stembedurl>https://stocktwits.com/GreenReaperx/message/602177528</stembedurl><stembedurl>https://stocktwits.com/SCNC/message/602177417</stembedurl>Aclarion specializes in Magnetic Resonance Spectroscopy (MRS) and augmented intelligence algorithms to help physicians pinpoint sources of chronic low back pain through its SaaS platform, Nociscan.&nbsp;Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.&nbsp;According to a regulatory filing, Aclarion raised about $300,000 in gross proceeds before canceling the deal, which was initiated in September 2024.Despite losing&nbsp;over 71% of its value over the past three months, Aclarion’s retail following on Stocktwits has surged 50%, with message volume soaring over 6,000%.Aclarion’s stock last had a short interest of 17.4%, according to Koyfin data.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Representative image of a stock chart | Image source: Maria Korneeva on Getty Images

Aclarion’s Retail Following Jumps 60% After Reverse Stock Split As Micro-Cap Health Tech Shares Nearly Double

Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.

Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. It utilizes Artificial Intelligence to assist in quality control processes that flag spectroscopy data indicative of a poor MRS study. It offers NOCISCAN Suite, a revolutionary software suite that works with existing high field Magnetic Resonance systems and Magnetic Resonance Spectroscopy pulse sequence packages using an optimized protocol to conduct MRS exams of lumbar discs. The company was founded by James C. Peacock, David S. Bradford, and Jeffrey Lotz in 2008 and is headquartered in Broomfield, CO.

Current Price	$3.79
Prev Close	$4.00
Open	$4.00
Dividend Yield	0.00%
50-Day Moving Average	$5.97
Beta	1.76
Avg. Volume	111,160.73
PE Ratio	0.00

52-Week High	$692.85
52-Week Low	$3.68
Market Capitalization	$4M
EPS (Annual)	-$7,480.22
Price to Book	0.18
Revenue Per Employee	$7,620.67
Enterprise Value/EBITDA	N/A

ACON
Aclarion Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ACON News

ACONAclarion Inc